/PRNewswire/ Biohaven Ltd. (NYSE: BHVN) (the "Company" or "Biohaven") today announced the closing of an underwritten public offering of 28,750,000 of its.
/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive.
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021
- Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020
News provided by
Share this article
Share this article
NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.
Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of March 31, 2021) were o
Message :
Required fields
NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.
Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of March 31, 2021) were over 500,000, with over 30,000 unique prescribers.
The foregoing information reflects the Company s estimate with respect to net product revenue for NURTEC ODT based on currently available information which is preliminary and unaudited, is not a comprehensive statement of the Company s financial results and is subject to completion of the Company s financial closing pr
Biohaven Provides Update On ESG Practices
News provided by
Share this article
Share this article
NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company s commitment to sound Environmental, Social and Governance ( ESG ) practices.
Maximizing long-term shareholder value and managing resources responsibly remains a key driving force for Biohaven s ESG strategy, with the Company dedicated to bringing innovative medicines forward for patients and to grow value for investors while maintaining an efficient and high-performing culture.